Kurz K
Z Hautkr. 1986 Nov 15;61(22):1646-53.
20 patients, 12 suffering from chronic urticaria, 2 from acute urticaria, 1 from pressure urticaria, 2 from cold urticaria and 3 from urticaria factitia were treated in an open pilot study with the new H1-antihistamine Astemizole. The dosage was in all cases 1 X 10 mg per day. The onset of action as well as the efficacy maximum were registered. Astemizole proved in this study to be a very effective antihistamine being able to achieve good results even in hard to cure cases like cold urticaria. On the 1. day 35% of the patients had noticed an onset of action. 75% of the patients had an onset of action within the first 2 days. The efficacy maximum was achieved within the first 2 days in 60% of the patients.
在一项开放性初步研究中,使用新型H1抗组胺药阿司咪唑对20例患者进行了治疗,其中12例患有慢性荨麻疹,2例患有急性荨麻疹,1例患有压力性荨麻疹,2例患有寒冷性荨麻疹,3例患有人工性荨麻疹。所有病例的剂量均为每日1次,每次10毫克。记录了起效时间以及最大疗效。在这项研究中,阿司咪唑被证明是一种非常有效的抗组胺药,即使在像寒冷性荨麻疹这样难以治愈的病例中也能取得良好效果。在第1天,35%的患者注意到有起效。75%的患者在头2天内起效。60%的患者在头2天内达到最大疗效。